Pentatricopeptide Repeat Protein Engineering Technology

EditForce is a biotechnology company specializing in the research and development of next-generation gene editing technologies based on PPR (pentatricopeptide repeat) proteins. By harnessing these engineered proteins, the company’s proprietary platform enables precise modulation of gene expression at the RNA level, targeting disease-causing mutations more accurately than traditional gene editing methods. This approach has the potential to address a wide spectrum of genetic disorders, including those that currently lack effective treatments, by leveraging the unique specificity and versatility of PPR-based editing.

Beyond its core PPR technology, EditForce continues to expand its pipeline to multiple therapeutic areas, such as inherited diseases, oncology, and regenerative medicine. Through strategic collaborations with academic institutions and industry partners, the company aims to translate its research breakthroughs into transformative therapies that can be scaled and delivered to patients worldwide. By integrating robust preclinical development with a patient-centric focus, EditForce positions itself at the forefront of innovative gene editing solutions.

Japan

Fukuoka Tenjin Fukoku Seimei Building, 1-9-17 Tenjin, Chuo, Fukuoka Prefecture, JP, 810-0001

EditForce

Company Details